You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,785,415

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,785,415 protect, and when does it expire?

Patent 8,785,415 protects MAVENCLAD and is included in one NDA.

This patent has sixty-eight patent family members in thirty-one countries.

Summary for Patent: 8,785,415

Patent landscape, scope, and claims:

Title:	Oral formulations of cladribine
Abstract:	Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.
Inventor(s):	Bodor; Nicholas S. (Bal Harbour, FL), Dandiker; Yogesh (Toronto, CA)
Assignee:	Ares Trading S.A. (Aubonne, CH)
Application Number:	12/986,310
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Process; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,785,415

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF MS WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE (2CDA) AND CYCLODEXTRIN AND (B) AMORPHOUS FREE 2CDA AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, FORMULATED AS A SOLID ORAL FORM, W/O SIGN. AMOUNTS OF CRYST. 2CDA	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,785,415

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1608344	⤷ Subscribe	PA2018502	Lithuania	⤷ Subscribe
European Patent Office	1608344	⤷ Subscribe	LUC00065	Luxembourg	⤷ Subscribe
European Patent Office	1608344	⤷ Subscribe	PA2018502,C1608344	Lithuania	⤷ Subscribe
European Patent Office	1608344	⤷ Subscribe	C 2018 009	Romania	⤷ Subscribe
European Patent Office	1608344	⤷ Subscribe	C 2018 010	Romania	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.